______________________________________________________________________________________________________________________________ Asia Europe North America ------------------------- ------------------------- ------------------------- Number of patients 3071 (100.0) 7108 (100.0) 3403 (100.0) Treatment group class 1 (N [%]) A 655 (21.3) 2565 (36.1) 849 (24.9) B 844 (27.5) 2687 (37.8) 892 (26.2) C 104 (3.4) 802 (11.3) 701 (20.6) D 91 (3.0) 350 (4.9) 224 (6.6) E 727 (23.7) 373 (5.2) 455 (13.4) F 0 (0.0) 5 (0.1) 7 (0.2) G 42 (1.4) 54 (0.8) 20 (0.6) H 608 (19.8) 272 (3.8) 255 (7.5) Treatment group class 2 (N [%]) X 572 (18.6) 2357 (33.2) 668 (19.6) Y 83 (2.7) 208 (2.9) 181 (5.3) Treatment group class 3 (N [%]) A 20 mg 227 (7.4) 1348 (19.0) 689 (20.2) A 30 mg 418 (13.6) 1193 (16.8) 83 (2.4) A 40 mg 0 (0.0) 11 (0.2) 74 (2.2) A other dose 10 (0.3) 13 (0.2) 3 (0.1)